Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 213 | 现货 | ||
5 mg | ¥ 467 | 现货 | ||
10 mg | ¥ 821 | 现货 | ||
25 mg | ¥ 1,660 | 现货 | ||
50 mg | ¥ 2,490 | 现货 | ||
100 mg | ¥ 3,730 | 现货 | ||
500 mg | ¥ 7,880 | 现货 |
产品描述 | NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1]. |
靶点活性 | Osteoclast:1.57 μM |
体外活性 |
NFATc1-IN-1 (0、0.5、1.0、1.5、2.0、2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM.[1] NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1.[1] |
分子量 | 375.11 |
分子式 | C13H8F2INO2 |
CAS No. | 1912422-56-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (299.9 mM ), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6659 mL | 13.3294 mL | 26.6588 mL | 66.6471 mL |
5 mM | 0.5332 mL | 2.6659 mL | 5.3318 mL | 13.3294 mL | |
10 mM | 0.2666 mL | 1.3329 mL | 2.6659 mL | 6.6647 mL | |
20 mM | 0.1333 mL | 0.6665 mL | 1.3329 mL | 3.3324 mL | |
50 mM | 0.0533 mL | 0.2666 mL | 0.5332 mL | 1.3329 mL | |
100 mM | 0.0267 mL | 0.1333 mL | 0.2666 mL | 0.6665 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NFATc1-IN-1 1912422-56-0 NF-Κb RANKL/RANK Inhibitor inhibitor inhibit